VIO Chemicals and SpiroChem Obtain a $500,000 Government Research Grant to Develop New Technologies to Drive Efficient Drive Drug Discovery
Summary
VIO Chemicals AG is headquartered in Zurich, Switzerland, and has offices and production facilities in Nanjing and Binhai (Jiangsu province), China.The CTI operates on the principle of subsidiarity through a number of closely linked funding areas, helping when innovations cannot be launched or their market potential remains untapped.Some quinuclidine-containing drugs have been present on the market for over 20 years and are facing loss of exclusivity, which creates the need for more efficient and economical processes.The second step for the project is to develop flow chemistry techniques in the production of intermediates for the use in pharmaceutical manufacturing on a commercial scale.VIO Chemicals AG is headquartered in Zurich, Switzerland, and has offices and production facilities in Nanjing and Binhai (Jiangsu province), China.To learn more, visit www.viochem.com.About SpiroChem AGSpiroChem AG is a fine chemicals company active in the field of high-value-added building blocks for the pharmaceuticals, agrochemicals and materials industries.SpiroChem designs, synthesizes and commercializes a large range of small molecule fragments used in drug discovery to improve the properties of drug candidates.The CTI operates on the principle of subsidiarity through a number of closely linked funding areas, helping when innovations cannot be launched or their market potential remains untapped.